- Home
- NPCE vs ABEO Comparison
NPCE vs ABEO Comparison
Compare NPCE & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPCE | ABEO |
|---|---|---|
| Founded | 1997 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.8M | 281.0M |
| IPO Year | 2021 | 1980 |
Fundamental Metrics
Financial Performance| Metric | NPCE | ABEO |
|---|---|---|
| Price | $16.43 | $5.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $17.00 | ★ $18.20 |
| AVG Volume (30 Days) | 233.2K | ★ 2.4M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | ★ $94,864,000.00 | $400,000.00 |
| Revenue This Year | $24.82 | N/A |
| Revenue Next Year | $1.28 | $1,590.36 |
| P/E Ratio | ★ N/A | $4.03 |
| Revenue Growth | ★ 24.08 | N/A |
| 52 Week Low | $7.56 | $3.93 |
| 52 Week High | $18.98 | $7.54 |
Technical Indicators
Market Signals| Indicator | NPCE | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 67.29 | 57.89 |
| Support Level | $15.61 | $4.53 |
| Resistance Level | $17.22 | $4.92 |
| Average True Range (ATR) | 0.95 | 0.26 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 83.66 | 85.71 |
Price Performance
Historical ComparisonAbout NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.